Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for standing by. Welcome to the Magical Pharmaceuticals Third Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead. Thanks, Marvin. Good morning, everyone, and thank you for joining us to discuss Madrigal's third quarter 2025 earnings. We issued a press release this morning and posted a slide deck that accompanies this webcast on the investor relations section of our website. On the call with me today is Bill Sibyl, Chief Executive Officer, Dave Sorgel, Chief Medical Officer, and Marty Deer, Chief Financial Officer. They will provide prepared remarks, and then we'll take your questions. Please note on slide two, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. With that, I will now turn the call over to Bill. Thanks, Tina. Good morning and thanks for joining us. We have delivered another excellent quarter as we continue to execute on our strategic priorities. We're maximizing the value of ResDifera and building our pipeline, which sets us up for continued value creation. ResDifera is quickly becoming one of the most successful specialty launches in the industry, with sales now annualizing at greater than $1 billion in only its sixth quarter of launch. More than 29,500 patients are being treated with ResDifera, and more than 10,000 healthcare providers have prescribed it. We've made great progress on our 2026 payer contracting st...